Study List:

Study 1:
  NCT Number:                   NCT02252770
  Title:                        Nitric Oxide Supplementation in Argininosuccinic Aciduria
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Argininosuccinic Aciduria|Argininosuccinate Lyase Deficiency|Urea Cycle Disorders
  Interventions:                Dietary Supplement: Nitric oxide supplement|Dietary Supplement: Placebo
  Outcome Measures:             Vascular endothelial function as assessed by FMD of brachial artery
  Sponsor/Collaborators:        Baylor College of Medicine
  Gender:                       All
  Age:                          8 Years to 64 Years   (Child, Adult)
  Phases:                       Not Applicable
  Enrollment:                   12
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    H-33236
  Start Date:                   September 2014
  Primary Completion Date:      October 2018
  Completion Date:              October 2018
  First Posted:                 September 30, 2014
  Results First Posted:         
  Last Update Posted:           January 18, 2018
  Locations:                    Texas Children's Hospital, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02252770

Study 2:
  NCT Number:                   NCT00345605
  Title:                        Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Argininosuccinic Aciduria|Amino Acid Metabolism, Inborn Errors|Urea Cycle Disorders
  Interventions:                Drug: Sodium Phenylbutyrate|Drug: Arginine
  Outcome Measures:             Measures of Liver Function: AST and ALT|Measures of Liver Function: PT and PTT|Measures of Liver Function: Coagulation Factors|Measures of Liver Function: INR|Argininosuccinic Acid Levels|Arginine Levels|Urea Production Rate
  Sponsor/Collaborators:        Brendan Lee|Office of Rare Diseases (ORD)|Rare Diseases Clinical Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Baylor College of Medicine
  Gender:                       All
  Age:                          5 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   12
  Funded Bys:                   Other|NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    RDCRN 5102|U54HD061221
  Start Date:                   February 2008
  Primary Completion Date:      May 2011
  Completion Date:              November 2012
  First Posted:                 June 28, 2006
  Results First Posted:         November 5, 2014
  Last Update Posted:           January 31, 2018
  Locations:                    Baylor College of Medicine, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00345605

Study 3:
  NCT Number:                   NCT03064048
  Title:                        Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Argininosuccinate Lyase Deficiency|Urea Cycle Disorder|Urea Cycle Disorders, Inborn|Argininosuccinic Aciduria
  Interventions:                Dietary Supplement: Neo-ASA|Dietary Supplement: Placebo
  Outcome Measures:             Delis-Kaplan Executive Function System - Tower subtest|Stanford-Binet - 4th Edition: Bead Memory and Sentence Memory subtests|Grip Strength|Grooved Pegboard|Wechsler Intelligence Scale for Children OR Wechsler Adult Intelligence Scale - 4th Edition (in subjects > 16 years of age)|Tower of London Test|Conners Continuous Performance Test - 3rd Edition Conners Continuous Performance Test - 3rd Edition
  Sponsor/Collaborators:        Baylor College of Medicine|Rare Diseases Clinical Research Network|Neogenis Laboratories
  Gender:                       All
  Age:                          6 Years to 50 Years   (Child, Adult)
  Phases:                       Not Applicable
  Enrollment:                   16
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    H-40143
  Start Date:                   September 15, 2017
  Primary Completion Date:      January 31, 2020
  Completion Date:              December 31, 2023
  First Posted:                 February 24, 2017
  Results First Posted:         
  Last Update Posted:           January 18, 2018
  Locations:                    Baylor College of Medicine, Houston, Texas, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03064048

Study 4:
  NCT Number:                   NCT01421888
  Title:                        The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Argininosuccinic Aciduria|Carbamoyl-Phosphate Synthase I Deficiency|Citrullinemia|Ornithine Carbamoyltransferase Deficiency|Hyperargininemia|N-Acetylglutamate Synthase Deficiency
  Interventions:                
  Outcome Measures:             
  Sponsor/Collaborators:        National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)
  Gender:                       All
  Age:                          2 Years to 99 Years   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   4
  Funded Bys:                   NIH
  Study Type:                   Observational
  Study Designs:                Time Perspective: Prospective
  Other IDs:                    110217|11-HG-0217
  Start Date:                   August 8, 2011
  Primary Completion Date:      
  Completion Date:              April 17, 2013
  First Posted:                 August 23, 2011
  Results First Posted:         
  Last Update Posted:           July 17, 2019
  Locations:                    National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01421888

Study 5:
  NCT Number:                   NCT01624311
  Title:                        Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Urea Cycle Disorders|Organic Acidemias
  Interventions:                Other: Therapeutic Hypothermia|Other: Standard of Care Therapy
  Outcome Measures:             Number of Participants with unexpected Serious Adverse Events as a Measure of Safety and Tolerability|Feasibility of hypothermia therapy as adjunct therapy to the complex standard of care therapy|Time to normalization of ammonia level
  Sponsor/Collaborators:        Uta Lichter-Konecki|Children's Research Institute|Medical College of Wisconsin|Columbia University
  Gender:                       All
  Age:                          up to 30 Days   (Child)
  Phases:                       Phase 2
  Enrollment:                   5
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    AAAN6104
  Start Date:                   August 2007
  Primary Completion Date:      May 2015
  Completion Date:              May 2015
  First Posted:                 June 20, 2012
  Results First Posted:         
  Last Update Posted:           June 1, 2015
  Locations:                    Children's National Medical Center, Washington, District of Columbia, United States|Columbia University, Morgan Stanley Children's Hospital, New York, New York, United States|Medical College Wisconsin, Milwaukee, Wisconsin, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01624311

